Boehringer Ingelheim and Eli Lilly and Company today announced the launch of the largest multinational survey to investigate early conversations between physicians and people living with Type 2 Diabetes (T2D). The survey was developed in partnership with the International Diabetes Federation (IDF) and will include more than 10,000 people with T2D and more than 6,500 treating-physicians across 26 countries worldwide. The findings will provide in-depth insights into early conversations at diagnosis and when an additional therapy may be required beyond the first medication. The survey will also investigate how these early conversations may be linked to an individual’s wellbeing and other self-reported outcomes.
Early and comprehensive management of T2D has been shown to lead to better outcomes and the reduction of diabetes-related complications. Effective communication between a person living with T2D and their physician right from diagnosis may increase the individual’s satisfaction and adherence, improve quality of life, enhance self-care, and may even improve blood glucose control and outcomes.